deferoxamine has been researched along with Infarction, Middle Cerebral Artery in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 7.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 5.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 3.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 1.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "Rat model of cerebral ischemia was established by middle cerebral artery occlusion with or without DFO administration." | 1.35 | Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. ( Ding, SJ; Guo, W; Li, YX; Xiao, L; Zhan, Q, 2008) |
| "Treatment with deferoxamine (DFO) is protective against focal ischemia with global hypoxia when given as a preconditioning stimulus in neonatal rodents." | 1.33 | Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. ( Chang, YS; Ferriero, DM; Mu, D; Vexler, ZS, 2005) |
| "Treatment with deferoxamine significantly decreased the size of brain damage (-28%) after ischemia and improved behavioral recovery." | 1.33 | Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. ( Bernaudin, M; Boulouard, M; Chazalviel, L; Freret, T; Mackenzie, ET; Petit, E; Saulnier, R; Schumann-Bard, P; Valable, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanson, LR | 1 |
| Roeytenberg, A | 1 |
| Martinez, PM | 1 |
| Coppes, VG | 1 |
| Sweet, DC | 1 |
| Rao, RJ | 1 |
| Marti, DL | 1 |
| Hoekman, JD | 1 |
| Matthews, RB | 1 |
| Frey, WH | 1 |
| Panter, SS | 1 |
| Xing, Y | 1 |
| Hua, Y | 1 |
| Keep, RF | 1 |
| Xi, G | 1 |
| Im, DS | 1 |
| Jeon, JW | 1 |
| Lee, JS | 1 |
| Won, SJ | 1 |
| Cho, SI | 1 |
| Lee, YB | 1 |
| Gwag, BJ | 1 |
| Mu, D | 1 |
| Chang, YS | 1 |
| Vexler, ZS | 1 |
| Ferriero, DM | 1 |
| Freret, T | 1 |
| Valable, S | 1 |
| Chazalviel, L | 1 |
| Saulnier, R | 1 |
| Mackenzie, ET | 1 |
| Petit, E | 1 |
| Bernaudin, M | 1 |
| Boulouard, M | 1 |
| Schumann-Bard, P | 1 |
| Li, YX | 1 |
| Ding, SJ | 1 |
| Xiao, L | 1 |
| Guo, W | 1 |
| Zhan, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for deferoxamine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Brain; Brain Ischemia; Deferoxamine; Dose-Res | 2009 |
Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia.
Topics: Animals; Blood-Brain Barrier; Body Water; Brain; Brain Chemistry; Brain Edema; Deferoxamine; Hemoglo | 2009 |
Role of the NMDA receptor and iron on free radical production and brain damage following transient middle cerebral artery occlusion.
Topics: Animals; Brain Damage, Chronic; Deferoxamine; Disease Models, Animal; Dizocilpine Maleate; Free Radi | 2012 |
Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke.
Topics: Animals; Animals, Newborn; Blotting, Western; Deferoxamine; Disease Models, Animal; Erythropoietin; | 2005 |
Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.
Topics: Animals; Behavior, Animal; Brain; Deferoxamine; Hypoxia-Inducible Factor 1, alpha Subunit; Infarctio | 2006 |
Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Deferoxamine; Disease Models, Animal; | 2008 |